CVAC CureVac
- 3.320
- -0.220-6.21%
CureVac News
Bird Flu Shots to Begin in Finland
Finland is set to become the first country to administer avian flu vaccinations, potentially as soon as next week.
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates.Quantum
CDC 'Preparing for the Possibility' Bird Flu Could Spread More Easily
Bird Flu May Have Brought Stock Advancement for CureVac, +11%
$CureVac(CVAC.US)$, a company testing trail vaccines for influenza, climbed 11% Thursday after in part the news of three cases of a new strain of bird flu in the U.S., called H5N1. The firm dosed a pa
Bird Flu Death in Mexico Linked to Strain Not Seen in Humans Before
Express News | 'First-ever Human Death of Bird Flu Strain H5N2 Confirmed in Mexico: WHO' -Global News
Express News | CureVac : Deutsche Bank Cuts Target Price to $5 From $6.5
Third Human Bird Flu Case Found in U.S.
CureVac Launches Phase 2 Study for Influenza Vaccine
Express News | CureVac Has Dosed The First Participant In Phase 2 Study Of The Multivalent Seasonal Influenza Vaccine Candidate Developed In Collaboration With GSK Against Influenza B Strain
Express News | CureVac NV Says CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration With GSK
CureVac N.V. (NASDAQ:CVAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
CureVac First Quarter 2024 Earnings: Misses Expectations
Revenues Not Telling The Story For CureVac N.V. (NASDAQ:CVAC) After Shares Rise 47%
CureVac N.V. (NASDAQ:CVAC) shareholders would be excited to see that the share price has had a great month, posting a 47% gain and recovering from prior weakness.
CureVac Announces 2024 AGM and Dividend Policy
CureVac Streamlines Operations, Advances Vaccine Trials
CureVac Reports Deepening Losses in Q1 2024
Express News | CureVac NV: Cash and Cash Equivalents Position of €300.2 Million as of March 31, 2024; Reaffirming Cash Runway Into Fourth Quarter of 2025
Express News | CureVac NV: Organizational Redesign on Track, Trimming Residual Pandemic Infrastructure and Reducing 150 Positions by Year End
CureVac | 6-K: Report of foreign private issuer (related to financial reporting)
Analysis
Price Target
No Data
